Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Research & Development (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Research & Development readings, the most recent being $17.0 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 6.28% to $17.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $69.5 million, a 1.16% decrease, with the full-year FY2025 number at $69.5 million, down 1.16% from a year prior.
  • Research & Development hit $17.0 million in Q4 2025 for Aligos Therapeutics, down from $23.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $31.7 million in Q1 2022 to a low of $14.0 million in Q2 2025.
  • Median Research & Development over the past 5 years was $18.0 million (2022), compared with a mean of $20.1 million.
  • Biggest five-year swings in Research & Development: plummeted 42.75% in 2023 and later surged 42.7% in 2025.
  • Aligos Therapeutics' Research & Development stood at $28.6 million in 2021, then tumbled by 33.21% to $19.1 million in 2022, then increased by 16.53% to $22.3 million in 2023, then dropped by 27.97% to $16.0 million in 2024, then rose by 6.28% to $17.0 million in 2025.
  • The last three reported values for Research & Development were $17.0 million (Q4 2025), $23.9 million (Q3 2025), and $14.0 million (Q2 2025) per Business Quant data.